Drug Shortage Tracker
FDA drug shortage data — 1,679 records tracked. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
1144
Current Shortages
494
To Be Discontinued
41
Resolved
Showing all 1,679 shortage records
Current Shortages (1144)
To Be Discontinued (494)
Discontinuation of the manufacture of the drug
A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.
A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of private label only
Discontinuation of private label only
Discontinuation of private label only
Discontinuation of private label only
Discontinuation of private label only
A business decision was made to discontinue manufacture of the drug
A business decision was made to discontinue manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Product to expire in March 2026; Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Product to expire in March 2026; Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Supply is expected to be depleted by 12/31/2025.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
To be discontinued December 1, 2025
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.
Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals
Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Business decision. Products will not be available after November 14, 2025.
Business decision. Products will not be available after November 14, 2025.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately February 28, 2026.
The 10 mg presentation remains available.
This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug. Product expected to be available through September 2026.
Discontinuation of the manufacture of the drug. Product expected to be available through July 2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Product not anticipated to be available beyond mid-late October 2025
Product not anticipated to be available beyond mid-late September 2025
A business decision was made to discontinue manufacture of the product.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Discontinuation of the manufacture of the drug product
Unbranded Insulin Aspart 3 mL PenFill® cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Degludec 3 mL U-200 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin aspart protamine and insulin aspart FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Aspart 3 mL FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation is for the “NovaPlus” label product only.
A business decision was made to discontinue.
A business decision was made to discontinue.
A business decision was made to discontinue.
Discontinuation of the manufacture of the drug. Supply expected to exhaust September 2025
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Product expected to be available until August 2025.
Product expected to be available until August 2025.
A business decision was made to discontinue manufacture of the product
A business decision was made to discontinue manufacture of the product
A business decision was made to discontinue manufacture of the product
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Permanent discontinuation in the manufacturing of the drug
Discontinuation of the manufacture of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Discontinuation of the manufacture of the drug
Permanent discontinuation in the manufacturing of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
A business decision was made to discontinue manufacture of the product.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Permanent discontinuation
Permanent discontinuation
Permanent discontinuation
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation in the manufacturing of the drug
Permanent discontinuation of manufacture due to business decision.
Permanent discontinuation of specific package size/ SKU for business reasons.
A business decision was made to discontinue the product.
A business decision was made to discontinue the product.
A business decision was made to discontinue the product.
A business decision was made to discontinue the product.
A business decision was made to discontinue the product.
A business decision was made to discontinue the product.
Discontinuation of the manufacture of the drug.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of manufacture of drug based on business decision.
Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023
Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.
This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031
This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031
Equivalent Sandoz format is available.
Equivalent Sandoz format is available.
Equivalent Sandoz format is available.
Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 5/31/2025
Last batch expiration date 8/31/2025
Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 10/31/2025
Last batch expiration date 5/31/2025
A business decision was made to discontinue manufacture of the drug.
Discontinuation due to low sales volume. Supply currently available with June 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.)
A business decision was made to discontinue manufacture of the drug.
Discontinuation due to low sales volume. Supply currently available with November 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.)
A business decision was made to discontinue.
A business decision was made to discontinue.
A business decision was made to discontinue.
Product is expected to be available through June 2027.
Product is expected to be available through February 2027.
A business decision was made to discontinue manufacture of the drug.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
A business decision was made to discontinue manufacture of the drug.
Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug.
Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026
Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug.
Discontinuing manufacture of the product as of June 2026.
Discontinuation of the manufacture of the drug
The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.
Equivalent Sandoz format is available.
Equivalent Sandoz format is available.
Equivalent Sandoz format is available.
Equivalent Sandoz format is available.
Equivalent Sandoz format is available.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
A business decision was made to discontinue manufacture of the drug.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
To be discontinued in approximately mid-2026.
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Discontinuation of the manufacture of the drug
Recently Resolved (41)
What to Do If Your Medication Is in Shortage
1. Contact Your Pharmacist
Your pharmacist can check other manufacturers and distributors for available supply.
2. Ask About Alternatives
Your prescriber can suggest therapeutic alternatives in the same drug class.
3. Don't Stockpile
Hoarding medications worsens shortages for everyone. Request only what you need.
Explore More
Frequently Asked Questions
What causes drug shortages?
How often is this data updated?
What should I do if my medication is in shortage?
Does a shortage mean I cannot get my medication?
Shortage Data Methodology
Shortage records are pulled directly from FDA Drug Shortages Database via the openFDA API. Status codes (Current, To Be Discontinued, Resolved), affected dosage forms, presentations, and manufacturer names are reproduced verbatim from FDA records. Therapeutic categories and brand-to-generic linkage leverage FDA SPL labels for cross-referencing. See the full methodology page for data vintage, processing pipeline, and interpretation caveats.
Disclaimer: This page provides information from the FDA Drug Shortages Database for educational purposes only. It is not medical advice. Always consult your healthcare provider or pharmacist about medication availability and alternatives. Do not stop or change any medication without professional guidance.